Last $12.79 USD
Change Today +1.00 / 8.48%
Volume 31.8K
LOXO On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

loxo oncology inc (LOXO) Snapshot

Open
$11.73
Previous Close
$11.79
Day High
$12.83
Day Low
$11.73
52 Week High
09/5/14 - $16.45
52 Week Low
01/21/15 - $9.90
Market Cap
212.7M
Average Volume 10 Days
23.2K
EPS TTM
--
Shares Outstanding
16.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LOXO ONCOLOGY INC (LOXO)

Related News

No related news articles were found.

loxo oncology inc (LOXO) Related Businessweek News

No Related Businessweek News Found

loxo oncology inc (LOXO) Details

Loxo Oncology, Inc., a development-stage company, develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its lead product candidate includes LOXO-101, an oral and selective inhibitor of tropomyosin receptor kinase, which is in a Phase I dose escalation trial for the treatment of patients with advanced solid tumor types, such as neuroblastoma and lung, thyroid, and breast cancers. The company is also developing a pipeline of additional product candidates targeting cancers driven by genetic alterations. Loxo Oncology, Inc. has a drug discovery collaboration agreement with Array BioPharma Inc. The company was founded in 2013 and is headquartered in Stamford, Connecticut.

9 Employees
Last Reported Date: 11/14/14
Founded in 2013

loxo oncology inc (LOXO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

loxo oncology inc (LOXO) Key Developments

Loxo Oncology, Inc. Appoints Alan Fuhrman as Independent Class Iii Director and Chair of the Audit Committee

On January 12, 2015, the Board of Directors of Loxo Oncology, Inc. appointed Alan Fuhrman as an independent Class III director and the Chair of the Audit Committee, with a term that will expire at Loxo's annual stockholder meeting in 2017. Mr. Fuhrman was CFO of Ambit Biosciences from October 2010 until its recent sale to Daiichi Sankyo for up to $410 million. Prior to this role, he served as CFO of Naviscan, Inc. from November 2008 until September 2010, and as CFO of Sonus Pharmaceuticals from September 2004 until August 2008.

Loxo Oncology, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Loxo Oncology, Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.

Loxo Oncology, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended Sep. 30, 2014

Loxo Oncology, Inc. announced unaudited earnings results for the third quarter and nine months ended Sep. 30, 2014. For the quarter, the company reported net loss attributable to common stockholders of $6,749,000 or $0.68 per basic and diluted share compared to $8,345,000 or $45.20 per basic and diluted share a year ago. For the nine months, the company reported net loss attributable to common stockholders of $13,584,000 or $3.87 per basic and diluted share compared to $8,345,000 or $71.52 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LOXO:US $12.79 USD +1.00

LOXO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LOXO.
View Industry Companies
 

Industry Analysis

LOXO

Industry Average

Valuation LOXO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LOXO ONCOLOGY INC, please visit www.loxooncology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.